Strategy for early diagnosis of pancreatic cancer

Exocrine pancreatic cancer, particularly Pancreatic Ductal Adenocarcinoma, is regarded as one of the most aggressive cancers with a poor prognosis. Its bleak outlook mainly results from its silent progression, late diagnosis, and unreliable early detection methods. Globally, PC ranks among the leading causes of cancer-related deaths, and its incidence continues to increase. Because the pancreas is situated deep within the abdomen, early symptoms such as mild abdominal pain, fatigue, or weight loss are often vague. Most patients are only diagnosed after the disease has spread beyond the point where curative treatment is possible. Although surgery provides the best chance for long-term survival, only a small number of patients qualify for it at the time of initial diagnosis. Several factors increase the risk of developing PC, including chronic pancreatitis, smoking, obesity, inherited genetic mutations (like BRCA1/2), and new-onset diabetes (NOD), which has recently gained attention as a possible early warning sign. However, widespread screening for PC isn’t yet practical because the disease is relatively uncommon and there are no highly accurate, non-invasive biomarkers. The most widely used blood test, CA 19-9, often gives unreliable results, while newer molecular approaches—like circulating tumor DNA, exosomal markers, microRNAs, and metabolomic profiles—are still being refined. Recent advances in imaging technology, artificial intelligence, and targeted screening for high-risk individuals hold promise for catching pancreatic cancer earlier. As we advance, combining multi-omics biomarkers with precision imaging may finally make earlier diagnosis—and improved survival—a reality for this devastating disease.